Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw unusually-high trading volume on Thursday . Approximately 369,693 shares changed hands during mid-day trading, an increase of 109% from the previous session’s volume of 177,106 shares.The stock last traded at $8.17 and had previously closed at $7.42.

FOMX has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Guggenheim reaffirmed a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 10th.

The company’s market cap is $261.20 million. The firm has a 50 day moving average price of $6.63 and a 200-day moving average price of $6.54.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.08. Equities analysts expect that Foamix Pharmaceuticals Ltd. will post ($0.89) EPS for the current year.

An institutional investor recently raised its position in Foamix Pharmaceuticals stock. J. Goldman & Co LP increased its position in shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned about 1.90% of Foamix Pharmaceuticals worth $4,704,000 at the end of the most recent reporting period.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.